Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.

Asad Ikram Joseph P DonnellyBrett W SperryChristy SamarasJason ValentMazen Hanna

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2018)

Diflunisal was well-tolerated in both the ATTRm- and ATTRwt-CA populations. Withdrawal due to side effects was related to gastrointestinal complaints, but most patients had no adverse events. Diflunisal can be safely used in a selected group of ATTR-CA patients with appropriate clinical, renal and hematologic monitoring.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
left ventricular
open label
clinical trial
patient reported outcomes
study protocol